Safety of Zoledronic Acid in Patients with Thalassemia Associated Low Bone Mineral Density
- 37 Downloads
Financial support was obtained from Shantha Biotech for DXA scans and zoledronic acid for these patients.
Compliance with Ethical Standards
Conflict of interests
All the authors declares that they have no conflict of interests.
Informed consent was obtained from all individual participants included in the study. This was part of DM thesis.
- 3.Voskaridou E, Christoulas D, Konstantinidou M, Tsiftsakis E, Alexakos P, Terpos E (2008) Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial. Haematologica 93(10):1588–1590CrossRefPubMedGoogle Scholar